Perspectives from expert roundtable: Strategies to attract funding for C&GT manufacturing tools

We share insights from investors on what they prioritize when evaluating funding opportunities for cell and gene therapy tools.

Developing an instrument that automates the cell and gene therapy workflow is no easy task. Your core tech, while critical, is only one part of the overall development, there is so much more that determines the success of your product. Brian Hanrahan shares 4 key tips for creating a successful cell therapy manufacturing tool.

Evident Corporation and Planet Innovation today announced a long-term strategic partnership to develop and manufacture innovative digital workflow solutions for life science markets.

Silicon Valley start-up LevitasBio has launched the world’s first label-free cell separation platform, the LeviCell™.

From start-ups to established companies, almost everyone in the life sciences and diagnostics industries is playing with digital health in one form or another. But how do you ensure this investment translates into commercial success for your company?

Cole-Parmer’s new Masterflex® Ismatec® Reglo Digital Pump series, is not so much an evolution, but a revolution of the popular peristaltic pump range.

IDEX Health & Science has launched the Tridex™ Protein Analyzer, which Planet Innovation helped develop, to measure protein titer directly from a bioreactor in real time.

Planet Innovation is partnering with Melbourne-based start-up Scinogy to manufacture a revolutionary new cell processing system that is being commercialized by global biotechnology company Thermo Fisher Scientific.

The AusBiotech National Conference, held in sunny Brisbane, brought together national and international leaders from across the life sciences industry. I took the opportunity to pop into a number of sessions on the growing AI and digital health sectors.

Pharmaceutical giant Merck Serono has signed an exclusive deal securing global marketing and commercialization rights to Genea Biomedx’s range of IVF products including Gavi and Geri, which were designed by Genea with development partner, Planet Innovation.

Tomas Stojanov has been an integral part of an extremely successful network of invitro-fertilisation (IVF) clinics in his role as the CEO of fertility group Genea, but his personal dream is to do more. He wanted to change the world of IVF to benefit his company, his industry and most importantly his patients.

Despite 30 years of IVF practice the process of freezing human embryos, known as vitrification, has remained extremely manual and susceptible to errors and inconsistencies by embryologists. In 2009, Genea Biomedx teamed up with Planet Innovation to solve this challenge by automating IVF vitrification and finally making the process consistent and standardised for labs around the world.